AbbVie
AbbVie Contract Manufacturing has been serving our partners for more than 35 years across ten of our manufacturing facilities located in both North America and Europe. Our contract development and manufacturing capabilities span both small and large molecule API including classical fermentation, chemical synthesis and biologics.
By choosing AbbVie Contract Manufacturing, your team gets so much more than the typical CMO engagement. Alongside our state of the art cGMP manufacturing facilities, AbbVie's partners gain integrated access to deep scientific expertise and processes that have successfully supported many small molecule and biologic medicines through to commercialization.
Information about AbbVie contract manufacturing services can be found at abbviecontractmfg.com or by reaching us directly at 1-847-938-8524. We look forward to serving you.
Contact Details:
Company name: AbbVie
Website: www.abbviecontractmfg.com
E-mail: abbviecontractmfg@abbvie.com
Stand/Booth number: 41M11
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
